Serotonin2C receptors modulate dopamine transmission in the nucleus accumbens independently of dopamine release: behavioral, neurochemical and molecular studies with cocaine

Addict Biol. 2015 May;20(3):445-57. doi: 10.1111/adb.12137. Epub 2014 Mar 24.

Abstract

In keeping with its ability to control the mesoaccumbens dopamine (DA) pathway, the serotonin2C receptor (5-HT2C R) plays a key role in mediating the behavioral and neurochemical effects of drugs of abuse. Studies assessing the influence of 5-HT2C R agonists on cocaine-induced responses have suggested that 5-HT2C Rs can modulate mesoaccumbens DA pathway activity independently of accumbal DA release, thereby controlling DA transmission in the nucleus accumbens (NAc). In the present study, we assessed this hypothesis by studying the influence of the 5-HT2C R agonist Ro 60-0175 on cocaine-induced behavioral, neurochemical and molecular responses. The i.p. administration of 1 mg/kg Ro 60-0175 inhibited hyperlocomotion induced by cocaine (15 mg/kg, i.p.), had no effect on cocaine-induced DA outflow in the shell, and increased it in the core subregion of the NAc. Furthermore, Ro 60-0175 inhibited the late-onset locomotion induced by the subcutaneous administration of the DA-D2 R agonist quinpirole (0.5 mg/kg), as well as cocaine-induced increase in c-Fos immunoreactivity in NAc subregions. Finally, Ro 60-0175 inhibited cocaine-induced phosphorylation of the DA and c-AMP regulated phosphoprotein of Mr 32 kDa (DARPP-32) at threonine residues in the NAc core, this effect being reversed by the selective 5-HT2C R antagonist SB 242084 (0.5 mg/kg, i.p.). Altogether, these findings demonstrate that 5-HT2C Rs are capable of modulating mesoaccumbens DA pathway activity at post-synaptic level by specifically controlling DA signaling in the NAc core subregion. In keeping with the tight relationship between locomotor activity and NAc DA function, this interaction could participate in the inhibitory control of cocaine-induced locomotor activity.

Keywords: 5-HT2C receptor; DARPP-32; c-Fos; dopamine release; locomotor activity; nucleus accumbens.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminopyridines / pharmacology
  • Animals
  • Cocaine / pharmacology*
  • Dopamine / metabolism
  • Dopamine Agonists / pharmacology
  • Dopamine Uptake Inhibitors / pharmacology*
  • Dopamine and cAMP-Regulated Phosphoprotein 32 / drug effects
  • Ethylamines / pharmacology
  • Indoles / pharmacology
  • Locomotion / drug effects
  • Male
  • Motor Activity / drug effects
  • Nucleus Accumbens / drug effects
  • Nucleus Accumbens / metabolism*
  • Phosphorylation / drug effects
  • Proto-Oncogene Proteins c-fos / metabolism
  • Quinpirole / pharmacology
  • Rats, Sprague-Dawley
  • Receptors, Serotonin, 5-HT2 / physiology*
  • Serotonin 5-HT2 Receptor Agonists / pharmacology
  • Synaptic Transmission / drug effects

Substances

  • 6-chloro-5-methyl-1-((2-(2-methylpyrid-3-yloxy)pyrid-5-yl)carbamoyl)indoline
  • Aminopyridines
  • Dopamine Agonists
  • Dopamine Uptake Inhibitors
  • Dopamine and cAMP-Regulated Phosphoprotein 32
  • Ethylamines
  • Indoles
  • Ppp1r1b protein, rat
  • Proto-Oncogene Proteins c-fos
  • Receptors, Serotonin, 5-HT2
  • Ro 60-0175
  • Serotonin 5-HT2 Receptor Agonists
  • Quinpirole
  • Cocaine
  • Dopamine